Principles of insulin therapy

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 659-670

  Cheng, Alice Y Y ^a   Zinman, Bernard ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971016589     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (123)

1. Banting FM, Best CH. The internal secretion of the pancreas. . Lab Clin Med 1922;7:256-271.
2. Bliss M. The discovery of insulin. Chicago: McClelland & Stewart, 1996.
3. Best CH. The first clinical use of insulin. Diabetes 1956;5:65-67.
4. Hagedorn HC, Jensen BN, Krarup NB, et al. Protamine insulinate. JAMA 1936;106:177-180.
5. Scott D, Fisher A. Studies on insulin with protamine. . Pharmacol Exp Ther 1936;58:78-92.
6. Krayenbuhl C, Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp 1946;1:60-73.
7. Riggs AD. Bacterial production of human insulin. Diabetes Care, 1984;4:64-68.
8. Howey DC, Bowsher RR, Brunelle R, et al. [Lys (B28), Pro (B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994;43: 396-402.
9. Zinman, B. The physiological replacement of insulin-an elusive goal. . Engl J Med 1989;321:363-370.
10. Lee WL, Zinman B. From insulin to insulin analogs: progress in the treatment of type 1 diabetes. Diabetes Rev 1998;6:73-88.
11. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am 1997;26: 575-598.
12. Heinemann L, Richter B. Clinical pharmacology of human insulin. Diabetes Care 1993;16[Suppl S3]:90-101.
13. Brunelle RL, Llewelyn J, Anderson JH, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21:1726-1731.
14. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment: Multicenter Insulin Lispro Study Group. Diabetes 1997;46; 265-270.
15. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analogue improves postprandial hyperglycemia and hypoglycemia in NIDDM patients. Arch Intern Med 1997;157:1249-1255.
16. Pfutzner A, Kustner E, Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol 1996;104:25-30.
17. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997;20:1827-1832.
18. Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998;159[Suppl 8]: S1-S29.
19. Ciofetta M, Lalli C, Del Sindaco P, et al. Contribution of postprandial versus interprandial blood glucose to Hb A1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999;22: 795-800.
20. Colombel A, Murat A, Krempf M, et al. Improvement of blood glucose control in type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999;16:319-324.
21. Mohn A, Matyka KA, Harris DA, et al. Lispro or regular insulin for multiple injection therapy in adolescence-differences in free insulin and glucose levels overnight. Diabetes Care 1999;22:27-32.
22. Ebeling P, Jansson P, Smith U, et al. Strategies toward improved control during insulin lispro therapy IDDM. Diabetes Care 1997;20:1287-1289.
23. Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22:468-477.
24. Zinman B, Tildesley H, Chiasson JL, et al. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1996;104:25-30.
25. Melki V, Renard E, Lassmann-Vague V, et al. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 1998;21:977-981.
26. Renner R, Pfutzner A, Trautmann M, et al. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999;22: 784-788.
27. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart: a fast acting analog of human insulin-absorption kinetics and action profile compared with reg-ular human insulin in healthy non-diabetic subjects. Diabetes Care 1999;22: 1501-1506.
28. Home PD, Lindhom A, Riis AP, et al. Improved long-term blood glucose control with insulin aspart versus human insulin in people with type 1 diabetes. Diabetes 1999;48 [Suppl 1]:A358(abst).
29. Uwe B, Ebrahim S, Hirshberger S, et al. Effect of the rapid acting insulin analogue insulin aspart on quality of life and treatment satisfaction in type 1 diabetic patients. Diabetes 1999;48[Suppl 1]:A112(abst).
30. Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23:583-588.
31. Raskin P, McGill J, Kilo C, et al. Human insulin analog (insulin aspart) is comparable to human insulin in type 2 diabetes. Diabetes 1999;48[Suppl 1]: A355(abst). 31a. Bode BW, Strange P. Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 2001;24:69-72.
32. Zinman B, Ross S, Campos RV, et al. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen: a double-blind randomized prospective trial. Diabetes Care 1999;22:603-608.
33. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22[Suppl 2]:B109-B113.
34. Luzio SD, Owens D, Evans M, et al. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects. Diabetes 1999;48[Suppl 1]:A111(abst).
35. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the longacting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649.
36. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23:639-643.
37. Rosenstock J, Park G, Zimmerman J, et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-1142.
38. Yki-Jarvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
39. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-445. 39a. Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996;39:281-288.
40. Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996;39:281-288
41. Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999;16:332-338.
42. Barnett AH. A review of basal insulins. Diabet Med 2003;20:873-885.
43. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27(5):1081-1087.
44. Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-596.
45. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998;21: 800-803.
46. Kovisto VA, Tuominen JA, Ebeling P. Lispro mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999;22:459-462.
47. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999;22:1258-1261.
48. Kapitza C, Rave K, Ostrowski K, et al. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med 2004;21:500-501.
49. Christiansen JS, Vaz JA, Metelko Z, et al. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003;5:446-454.
50. Coscelli C, Clabrese G, Fedele D, et al. Use of premixed insulin among the elderly. Diabetes Care 1992;15:1628-1630.
51. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complication in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
52. Reichard P, Britz A, Carlsson P, et al. Metabolic control and complications over 3 years in patients with insulin dependent diabetes (IDDM): the Stockholm Diabetes Intervention Study (SDIS). . Intern Med 1990;228:511-517.
53. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-568.
54. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. . Engl J Med 2000;342:381-389.
55. Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. Diabetes Care 1999;22[Suppl 2]:B35-B39.
56. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factor in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
57. American Diabetes Association. Implications of the diabetes control and complications trial: clinical practice recommendations 2001. Diabetes Care 2001;24[Suppl 1]:S25-S27.
58. Bolli GB. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 1999;22[Suppl 2]:B43-B52.
59. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 1997;46: 271-286.
60. Pampanelli S, Fanelli C, Lalli C, et al. Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycemia, status of counterregulation and awareness of hypoglycemia. Diabetologia 1996;39: 677-686.
61. Schiel R, Muller UA, Ulbrich S. Long-term efficacy of a 5-day structured teaching and treatment programme for intensified conventional insulin therapy and risk for severe hypoglycemia. Diabetes Res Clin Pract 1997;35:41-48.
62. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. . Engl J Med 1992;327:1426-1433.
63. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas of insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
64. Okhubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
65. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
66. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-419.
67. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study: Clinical practice recommendations 2001. Diabetes Care 2001;24[Suppl 1]: S28-S32. 60a.Gæde P, Pernille V, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. . Engl J Med 2003;348: 383-393.
68. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction-DIGAMI Study Group (Diabetes Insulin-Glucose in Acute Myocardial Infarction). Eur Heart J 1996;17:1298-1301.
69. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus (DIGAMI). BMJ 1997;314:1512-1515.
70. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2004;27[Suppl 1]:S15-S35.
71. American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004;27[Suppl 1]:S58-S62.
72. Wolfenbuttel BH, Sels JJ, Rondas-Colbers GJ, et al. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996;19: 1326-1332.
73. Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 1999;130: 389-396.
74. Relimpio F, Pumar A, Losada F, et al. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial. Diabet Med 1998;15:997-1002.
75. Buse JB, Bumbiner B, Mathias NP, et al. Troglitazone use in insulin-treated type 2 diabetic patients. Diabetes Care 1998;21:1455-1461.
76. Schwartz S, Raskin P, Fonsec V, et al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. . Engl J Med 1998;338:861-866.
77. Fonseca V, Graveline J, Nissel J. Long term experience with troglitazone in combination with insulin in type 2 diabetes mellitus. Diabetes 1998;47[Suppl 1]:A90(abst).
78. Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999;22:1568-1577.
79. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355: 1008-1010.
80. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am 1997;26:599-610.
81. Guerci B, Meyer L, Salle A, et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. . Clin Endocrinol Metab 1999;84:2673-2678.
82. Reichel A, Rietzsch H, Kohler HJ, et al. Cessation of insulin infusion at nighttime during CSII-therapy: comparison of regular human insulin and insulin lispro. Exp Clin Endocrinol Diabetes 1998;106:168-172.
83. Attia N, Jones TW, Holcombe J, et al. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998; 21:817-821.
84. American Diabetes Association. Insulin administration: clinical practice recommendations. Diabetes Care 2001;24[Suppl 1]:S94-S97.
85. Vaag A, Handberg A, Lauritzen M, et al. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 1990;13:74-76.
86. Skyler JS. Insulin pharmacology. Med Clin North Am 1988;72:1337-1354.
87. Bott S, Bott U, Berger M, et al. Intensified insulin therapy and risk of severe hypoglycaemia. Diabetologia 1997;40:326-932.
88. McCrimmon RJ, Frier BM. Hypoglycemia, the most feared complication of insulin therapy. Diabet Metab 1994;20:503-512.
89. The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1415-1427.
90. Gerstein HC, Capes S. Advantages and perceived disadvantages of insulin therapy for patients with type 2 diabetes. Can J Diab Care 1999;23[Suppl 2]: 91-94.
91. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158:134-140.
92. Gerich JE, Campbell PJ. Overview of counterregulation and its abnormalities in diabetes mellitus and other conditions. Diabetes Metab Rev 1988;4:93-111.
93. Trischitta V, Italia S, Mazzarino S. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992;15:539-543.
94. Torbay N, Bracco E, Geliebter A, et al. Insulin increases body fat despite control of food intake and physical activity. Am J Physiol 1985;258:R2120-R2144.
95. Field JB. Chronic insulin resistance. Acta Diabetol Lat 1970;7:220-242.
96. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-160.
97. Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as a coronary heart disease risk factors: relationship to other risk factors and predictive value over 9.5 year follow up of the Helsinki Policemen Study population. Acta Med Scand 1985;701:7-14.
98. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356-361.
99. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris prospective study. Diabetes Care 1991;14:431-469.
100. Nishimoto Y, Miyazaki Y, Toki Y, et al. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. . Am Coll Cardiol 1998;32:1642-1649.
101. Fujiwara R, Kursumi Y, Hayashi T, et al. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol 1995;75:122-126.
102. Kuusisto J, Mykkanen L, Pyorala K, et al. Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 1995;91: 831-837.
103. Yudkin JS, Denver AE, Mohamed-Ali V, et al. The relationship of concentrations of insulin and proinsulin-like molecules with coronary heart disease prevalence and incidence. Diabetes Care 1997;20:1093-1100.
104. Folsom AR, Szklo M, Stevens J, et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. Diabetes Care 1997; 20:935-942.
105. Mykkanen L, Laakso M, Pyorala K. High plasma insulin level associated with coronary heart disease in the elderly. Am J Epidemiol 1993;137:1190-1202.
106. Katz RJ, Ratner RE, Cohen RM, et al. Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes 1996;45: 736-741.
107. Hauhan A, Foote J, Petch MC, et al. Hyperinsulinemia, coronary artery disease and syndrome X. . Am Coll Cardiol 1994;23:364-368.
108. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-246.
109. Winter LB. On the absorption of insulin from the stomach. . Physiol 1923;58: 18-21.
110. Cefalu WT. Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med 2001;33:579-586.
111. Modi P, Mihic M. Replacement of sc injections with Oralin in treatment of diabetes. Diabetes Care 2001;50:179.
112. Yamasaki Y, Shichiri M, Kawamori R, et al. The effectiveness of rectal administration of insulin suppository on normal and diabetic subjects. Diabetes Care 1981;4:454-458.
113. Lee S, McAuliffe DJ, Mulholland SE, et al. Photomechanical transdermal delivery of insulin in vivo. Lasers Surg Med 2001;28:282-285.
114. Kanikkannan N, Singh J, Ramarao P. Transdermal iontophoretic delivery of bovine insulin and monomeric human insulin analogue. . Control Release 1999;59:99-105.
115. Laube BL. Treating diabetes with aerosolized insulin. Chest 2001;120: 99S-106S.
116. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997;14:63-72.
117. Laube BL, Benedict GW, Dobs AS. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. . Aerosol Med 1998;11:153-173.
118. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet 2001; 357:331-533.
119. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001;134:795.
120. Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type 1 diabetic patients. Diabetologia 2001;44: 305-308.
121. Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000;2:185-197.
122. Steiner S, Pfutzner A, Wilson BR, et al. Technosphere/Insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17-21.
123. Chan NN, Baldewag S, Tan TMN, et al. Inhaled insulin in type 2 diabetes [Letter]. Lancet 2001;357:1979.